Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department
Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.
Trump Taps Vaccine Skeptic RFK Jr. to Lead HHS. Moderna, Novavax Stock Slide.
Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic and harsh critic of federal health agencies, to be his Secretary of Health and Human Services. Trump announced the nomination in a post on Truth Social.
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services. Health policy experts have said a second Trump term could allow Kennedy to elevate anti-vaccine rhetoric.
Pharma stocks fall as Trump picks vaccine skeptic Robert F. Kennedy Jr. for US health job
Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration.
Trump taps Robert F. Kennedy Jr., vaccine skeptic, to lead HHS
The nearly $2 trillion agency administers health-insurance programs for millions of Americans, approves medications and oversees vaccine safety.
Trump Picks Vaccine Skeptic Robert F. Kennedy Jr. to Lead Health & Human Services
In a move guaranteed to alarm many, President-elect Donald Trump has chosen Robert F. Kennedy Jr., a vocal opponent of vaccines and other tenets of mainstream health care, to head the massive U.S. Department of Health and Human Services (HHS).
Public Health Experts Groan as RFK Jr. Pitches Vaccines as 'Personal Choice'
Vaccines are most effective at scale when enough people get them to provide "herd immunity" from a virus, doctors and officials say.
Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job
Shares of major U.S. drugmakers fell on Friday after President-elect Donald Trump picked anti-vaccine activist Robert F. Kennedy Jr. to head the Department of Health and Human Services, the top U.S. health agency.
Health stocks are tumbling after Trump's appointment of vaccine skeptic RFK Jr.
Vaccine stocks have struggled since RFK Jr.'s appointment to health secretary, with Moderna and Pfizer seeing the deepest losses.
Moderna, with aid of TBWA\Chiat\Day, is making mRNA science exciting & accessible
With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
FiercePharma8d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
BioSpace8d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Reuters8d
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 ...
Morrison government’s $2 billion vaccine deal blasted
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Moderna is a ‘show-me story’ heading into Q3 earnings
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...